

**Fund 129 - Opioid Settlement Fund**

<b>PROCEEDS</b>				
<b>Company</b>	<b>FY 23</b>	<b>FY 24</b>	<b>Total all FYs</b>	<b>Payments stop</b>
Allergan	\$2,909.16	\$5,687.22		Jul-29
CVS	\$1,362.88	\$11,382.11		Jun-32
Distributors	\$29,653.59	\$25,230.19		2040
Janssen	\$30,905.99	\$18,734.96		Jun-31
Teva	\$19,595.84	\$9,512.39		Jun-35
Walgreens	\$1,970.11	\$16,088.11		Jul-28
Walmart	\$0.00	\$102,586.81		Dec-36
<b>SUBTOTAL</b>	<b>\$86,397.57</b>	<b>\$189,221.79</b>	<b>\$275,619.36</b>	

<b>ADMINISTRATIVE COSTS (MAX 5%)</b>				
Less 5% admin fee	\$4,319.88	\$9,461.09	<b>\$13,780.97</b>	allocated to CED for salaries and materials/supplies

<b>TOTAL</b> (less 5% admin fee)	\$82,077.69	\$179,760.70	<b>\$261,838.39</b>	<b>Funding available for grant award</b>
----------------------------------------	-------------	--------------	---------------------	----------------------------------------------

Interest	\$1,841.39	\$5,084.50	<b>\$6,925.89</b>
----------	------------	------------	-------------------

All interest collected from prior FY funds will be applied to the next FY RFA for award because interest value will continue to fluctuate until funds are exhausted.

Available Funds*	<u><u>\$261,838.39</u></u>
------------------	----------------------------

\*less interest and 5% admin costs